Pathology Software Adds AI Gene Prioritization Tool

GO Pathology Workbench now includes Jalapheno, a phenotype-matching tool built by ARUP Laboratories, with optional AI-drafted variant interpretations.

Updated on Nov. 5, 2026 in Biotech

Pathology Software Adds AI Gene Prioritization Tool

GenomOncology will license and distribute Jalapheno, a phenotype-driven gene prioritization tool developed by ARUP Laboratories with the University of Utah, under a multiyear exclusive agreement with ARUP. Jalapheno is fully integrated into GO Pathology Workbench and available to all GenomOncology customers; specific terms of the agreement were not disclosed.

Why it matters

The deal places a phenotype-matching tool directly inside a widely used pathology software platform, reflecting a trend of genomic interpretation software absorbing AI-assisted classification into routine clinical workflows. GenomOncology also introduced optional AI-driven workflows for variant classification and interpretation at the same time.

Jalapheno generates gene-level phenotype-matching scores from patient Human Phenotype Ontology (HPO) terms, which feed into the broader variant prioritization algorithm. No accuracy or speed figures were disclosed in the announcement.

The players

GenomOncology

Cleveland-based software company that builds GO Pathology Workbench, a platform for pathology and genomic test interpretation.

ARUP Laboratories

Salt Lake City-based clinical reference laboratory that developed Jalapheno and is granting GenomOncology exclusive distribution rights.

University of Utah

Research university that collaborated with ARUP Laboratories in developing the Jalapheno gene prioritization tool.

The details

Jalapheno scores each candidate gene by how well its known associations match a patient's observed phenotypes, which are encoded as standardized Human Phenotype Ontology (HPO) terms, a controlled vocabulary of clinical features. These gene-level scores feed into the variant prioritization algorithm inside GO Pathology Workbench, which ranks genetic variants for review. The software also supports ACMG variant classification, the American College of Medical Genetics framework for labeling variants as benign, likely benign, uncertain, likely pathogenic, or pathogenic, along with ClinGen annotations and whole exome and whole genome workflows. For likely pathogenic or pathogenic variants, the optional AI feature automatically drafts a clinical interpretation, which a reviewer must edit and approve before the report is signed out.

Timeline

  1. November 5, 2026: GenomOncology and ARUP announced the multiyear exclusive agreement.

The Tech Race

The announcement places AI-assisted interpretation inside an established pathology platform rather than a standalone research tool. Competing genomic interpretation software vendors have not been named in the source material, so the competitive position relative to rivals is not established.

Because Jalapheno is already available to all GenomOncology customers, pathology labs using GO Pathology Workbench can access it now without a separate integration. The optional AI interpretation workflow requires reviewer approval before sign-out, and no pricing or timeline for broader rollout was disclosed.

The takeaway

Labs adopting GO Pathology Workbench will be able to test whether phenotype-driven prioritization changes how quickly likely pathogenic variants reach reviewers. Watch for published validation data or disclosed pricing that would show whether the AI-drafted interpretations hold up under clinical review.

Further reading

For broader context, explore the latest Biotech coverage on how software is reshaping clinical genomic interpretation.